Abstract PL01-02: Immune checkpoint therapy: From CTLA-4 to PD-1/PD-L1 and beyond
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-pl01-02
Abstract: Immune checkpoint therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1, have led to significant clinical responses in cancer patients. However, there are still substantial numbers of patients who do not respond to anti-CTLA-4 or anti-PD-1/PD-L1. We and… read more here.
Keywords: immune checkpoint; checkpoint therapy; therapy ctla; checkpoint ... See more keywords